The landscape of chromothripsis across adult cancer types

Natalia Voronina(German Cancer Research Center), John Wong(German Cancer Research Center), Daniel Hübschmann(German Cancer Research Center), Mario Hlevnjak(Heidelberg University), Sebastian Uhrig(Heidelberg University), Christoph E. Heilig(German Cancer Research Center), Peter Horak(German Cancer Research Center), Simon Kreutzfeldt(German Cancer Research Center), Andreas Möck(German Cancer Research Center), Albrecht Stenzinger(Heidelberg University), Barbara Hutter(Heidelberg University), Martina Fröhlich(Heidelberg University), Benedikt Brors(Heidelberg University), Arne Jahn(German Cancer Research Center), Barbara Klink(German Cancer Research Center), Laura Gieldon(German Cancer Research Center), Lina Sieverling(Heidelberg University), Lars Feuerbach(Heidelberg University), Priya Chudasama(Heidelberg University), Katja Beck(German Cancer Research Center), Matthias Kroiß(Universitätsklinikum Würzburg), Christoph Heining(German Cancer Society), Lino Möhrmann(German Cancer Society), Andrea Fischer(German Cancer Research Center), Evelin Schröck(German Cancer Research Center), Hanno Glimm(German Cancer Society), Marc Zapatka(German Cancer Research Center), Peter Lichter(German Cancer Research Center), Stefan Fröhling(German Cancer Research Center), Aurélie Ernst(German Cancer Research Center)
Nature Communications
May 8, 2020
Cited by 193Open Access
Full Text

Abstract

Chromothripsis is a recently identified mutational phenomenon, by which a presumably single catastrophic event generates extensive genomic rearrangements of one or a few chromosome(s). Considered as an early event in tumour development, this form of genome instability plays a prominent role in tumour onset. Chromothripsis prevalence might have been underestimated when using low-resolution methods, and pan-cancer studies based on sequencing are rare. Here we analyse chromothripsis in 28 tumour types covering all major adult cancers (634 tumours, 316 whole-genome and 318 whole-exome sequences). We show that chromothripsis affects a substantial proportion of human cancers, with a prevalence of 49% across all cases. Chromothripsis generates entity-specific genomic alterations driving tumour development, including clinically relevant druggable fusions. Chromothripsis is linked with specific telomere patterns and univocal mutational signatures in distinct tumour entities. Longitudinal analysis of chromothriptic patterns in 24 matched tumour pairs reveals insights in the clonal evolution of tumours with chromothripsis.


Related Papers

No related papers found

Powered by citation graph analysis